CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 130 target
Drug / intervention
tissue plasminogen activator +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00283088
NCT00283088Phase 1Completed
CompareCT.gov

Phase 1 Study of Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

University of California, San Diego·interventional·Posted Jan 27, 2006·Updated Jan 12, 2011

In Brief

A Phase 1 clinical trial evaluating hypothermia and tissue plasminogen activator for Stroke. Completed, enrolled 130 participants across 7 sites.

Detailed Summary

The purpose of this trial is to evaluate if it is safe to use tissue plasminogen activator (tPA) within 6 hours of stroke onset when combined with hypothermia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2006
Enrollment StartOct 1, 2003
Primary CompletionOct 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 20.4 years ago

Interventions

hypothermiaprocedure

Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System. Subjects are stratified by time to six groups.

tissue plasminogen activatordrug

tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots